We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+5.02%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$500M
AUM Growth
-$115M
Cap. Flow
-$85.2M
Cap. Flow %
-17.03%
Top 10 Hldgs %
48.26%
Holding
330
New
47
Increased
56
Reduced
65
Closed
116

Top Buys

Rank Stock Value
1
ZLAB icon
Zai Lab
ZLAB
+$14.3M
2
IKT icon
Inhibikase Therapeutics
IKT
+$12.7M
3
BIL icon
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
+$10.1M
4
ABVX
Abivax
ABVX
+$9.13M
5
RVMD icon
Revolution Medicines
RVMD
+$6.34M

Top Sells

Rank Stock Value
1
RPRX icon
Royalty Pharma
RPRX
+$27.8M
2
CYTK icon
Cytokinetics
CYTK
+$25.8M
3
KROS icon
Keros Therapeutics
KROS
+$21.9M
4
BBIO icon
BridgeBio Pharma
BBIO
+$19.9M
5
ASND icon
Ascendis Pharma A/S
ASND
+$11.8M

Sector Composition

Rank Sector Weight
1 Healthcare 77.69%
2 Financials 3.07%
3 Communication Services 1.32%
4 Technology 0.33%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GPCR icon
76
Structure Therapeutics
GPCR
$3.74B
$958K 0.19%
+35,319
New +$1.25M
BEAM icon
77
Beam Therapeutics
BEAM
$2.81B
$950K 0.19%
38,312
-5,588
-13% -$143K
MLTX icon
78
MoonLake Immunotherapeutics
MLTX
$1.53B
$944K 0.19%
17,424
-6,033
-26% -$308K
PFE icon
79
Pfizer
PFE
$149B
$930K 0.19%
35,050
-900
-3% -$24.4K
FULC icon
80
Fulcrum Therapeutics
FULC
$288M
$922K 0.18%
196,248
+140,446
+252% +$518K
DHR icon
81
Danaher
DHR
$141B
$918K 0.18%
+4,000
New +$983K
DNLI icon
82
Denali Therapeutics
DNLI
$3.92B
$914K 0.18%
44,826
-57,000
-56% -$1.46M
SRRK icon
83
Scholar Rock
SRRK
$6.41B
$843K 0.17%
19,505
+7,505
+63% +$244K
ANSC
84
Agriculture & Natural Solutions Acquisition Corp
ANSC
$476M
$843K 0.17%
80,362
– –
SPRO icon
85
Spero Therapeutics
SPRO
$73.5M
$825K 0.16%
801,277
+57,818
+8% +$68.8K
KVACU
86
DELISTED
Keen Vision Acquisition Corp Units
KVACU
$824K 0.16%
75,000
– –
ATXS
87
DELISTED
Astria Therapeutics
ATXS
$813K 0.16%
90,984
-2,300
-2% -$24.4K
CAPR icon
88
Capricor Therapeutics
CAPR
$242M
$774K 0.15%
56,120
+31,813
+131% +$557K
NMRA icon
89
Neumora Therapeutics
NMRA
$304M
$727K 0.15%
+68,608
New +$822K
VYGR icon
90
Voyager Therapeutics
VYGR
$189M
$719K 0.14%
126,792
+86,158
+212% +$555K
BIOA
91
BioAge Labs
BIOA
$517M
$712K 0.14%
+123,037
New +$2.12M
CYTK icon
92
CALL
Cytokinetics
CYTK
$11B
$710K 0.14%
15,100
– –
ALEC icon
93
Alector
ALEC
$203M
$696K 0.14%
368,330
-60,472
-14% -$228K
ALNY icon
94
Alnylam Pharmaceuticals
ALNY
$28.9B
$682K 0.14%
+2,900
New +$763K
INDV icon
95
Indivior Pharmaceuticals
INDV
$4.56B
$672K 0.13%
54,057
– –
DAWN
96
DELISTED
Day One Biopharmaceuticals
DAWN
$672K 0.13%
53,023
-88
-0.2% -$1.22K
CDTX
97
DELISTED
Cidara Therapeutics
CDTX
$670K 0.13%
+24,938
New +$405K
KPRX icon
98
Kiora Pharmaceuticals
KPRX
$11.3M
$661K 0.13%
200,221
+3,670
+2% +$12.7K
TARA icon
99
Protara Therapeutics
TARA
$230M
$648K 0.13%
+122,690
New +$396K
AKRO
100
CALL
DELISTED
Akero Therapeutics
AKRO
$626K 0.13%
22,500
– –
2 3
4
5 6

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return

ADAR1 Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, ADAR1 Capital Management held 330 positions worth $500M, down 19% from $615M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

ADAR1 Capital Management withdrew a net $85.2M in Q4 2024, closing 116 positions and reducing 65 holdings. Its most notable exit was Syndax Pharmaceuticals, an estimated $6.74M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 86% a quarter earlier, followed by Financials and Communication Services.

Against the trend, ADAR1 Capital Management opened a new position in Inhibikase Therapeutics worth $16.6M.

  • ADAR1 Capital Management's largest Q4 2024 buy was Inhibikase Therapeutics: 5,103,005 shares worth $16.6M.
  • ADAR1 Capital Management added most to Zai Lab in Q4 2024, an estimated $14.3M increase.
  • ADAR1 Capital Management's biggest Q4 2024 reduction was Royalty Pharma, cutting an estimated $27.8M.
  • ADAR1 Capital Management fully exited Syndax Pharmaceuticals in Q4 2024, selling an estimated $6.74M.
  • ADAR1 Capital Management's ten largest holdings make up 48% of its $500M portfolio in Q4 2024.
  • ADAR1 Capital Management opened 47 new positions and closed 116 in Q4 2024.
  • ADAR1 Capital Management's portfolio value fell 19% quarter-over-quarter to $500M.

Based on ADAR1 Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.